Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00223496
Status:
COMPLETED
Last Update Posted:
2017-05-16
First Post:
2005-09-14
Brief Title:
12- Week Open Label Treatment of Refractory Bipolar Depression
Sponsor:
The University of Texas Health Science Center at San Antonio
Organization:
The University of Texas Health Science Center at San Antonio
Study Overview
Official Title:
12- Week Open Label Treatment of Refractory Bipolar Depression BD With Combination of Depakote ER DEP and Aripiprazole AZP
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Determine the change in symptomatology and function in refractory bipolar depression when treated with combination of DEPAZP for a period of 12 weeks
2 Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
2 Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
Detailed Description:
Determine the change in symptomatology and function in refractory bipolar depression when treated with combination of DEPAZP for a period of 12 weeks
2 Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
2 Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None